Business
Editas Medicine Announces Second Quarter 2022 Results and Business Updates
Appointed Baisong Mei, M.D., Ph.D., Chief Medical Officer, strengthening senior leadership team Achieved successful engraftment of first patient treated with
About this update from Editas Medicine, Inc.
[{"type":"text","content":"Appointed Baisong Mei, M.D., Ph.D., Chief Medical Officer, strengthening senior leadership team Achieved successful engraftment of first patient treated with EDIT-301 for sickle cell disease; first clinical use of Editas-engineered AsCas12a enzyme FDA removed partial clinical hold for RUBY trial of EDIT-301 Continued screening and enrolling new adult and pediatric patients for EDIT-101 Phase 1/2 BRILLIANCE study for LCA10, with clinical data update expected 2H 2022 On track to initiate IND-enabling studies of EDIT-103 for RHO-adRP by year-end; pre-IND FDA meeting feedback supports continued development Entered research collaboration and licensing agreement with Immatics to develop cancer medicines, combining Immatics gamma-delta T cell adoptive cell therapies and Editas Medicine’s gene editing technology CAMBRIDGE, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the second quarter of 2022. “Since joining Editas Medicine two months ago, my review of the innovative technologies, strong CMC capabilities, and talented team has reinforced my enthusiasm about the company’s potential. I see tremendous value in our technology and ability to develop novel medicines, and I intend to focus our efforts on transforming the business from a technology platform company into a therapeutics company,” said Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer, Editas Medicine. “In addition, I’m excited to welcome our new Chief Medical Officer, Dr. Baisong Mei, to the leadership team, where he will utilize his deep experience in developing therapeutics from pre-clinical stages through global approvals to assist in this transformation.” Recent Achievements and Outlook Ex Vivo Gene Edited Medicines EDIT-301 for Sickle Cell DiseaseFirst SCD patient treated with EDIT-301 successfully engrafted and demonstrated positive initial safety profile Editas Medicine dosed the first patient and confirmed successful neutrophil and platelet engraftment in the Phase 1/2 RUBY trial for the treatment of severe sickle cell disease (SCD).This is the first time that the Company’s engineered AsCas12a enzyme has been used to edit human cells in a clinical trial.The Company is enrolling additional study participants, has successfully...